Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Cost per Responder Analysis to Assess the Value of CAR-T Therapy for Relapsed or Refractory Multiple Myeloma

Thomas Martin, Saad Z. Usmani, Nedra Joseph, Concetta Crivera, Satish Valluri, Carolyn C. Jackson, Lucas Cohen, Sumeet Singh, Sundar Jagannath

Blood (2021) 138 (Supplement 1): 4961.

https://doi.org/10.1182/blood-2021-146237

Published: 2021

Journal Articles

Total Car-T Cost of Care Beyond the Price of Car-T Cell Therapy in Patients with Multiple Myeloma

Sundar Jagannath, Nedra Joseph, Concetta Crivera, Carolyn C. Jackson, Satish Valluri, Patricia Cost, Hilary Phelps, Rafal Slowik, Timothy Klein, Xueting Yu, Lee Smolen, Adam D Cohen

Blood (2021) 138 (Supplement 1): 4964.

https://doi.org/10.1182/blood-2021-153438

Published: 2021

Journal Articles

Considerations for Optimal Administration of Chimeric Antigen Receptor (CAR) T-Cell Therapy Programs: A Multi-Stakeholder Qualitative Analysis

Daanish Hoda, Edward Faber, Jr., Bradley Hunter, Abhinav Deol, Concetta Crivera, Carrie Riccobono, Ashraf Garrett, Carolyn C. Jackson, Jessica Fowler, Ariel Berger, Andrea L Lorden, Raj Stewart

Blood (2021) 138 (Supplement 1): 1932.

https://doi.org/10.1182/blood-2021-145943

Published: 2021

Journal Articles

Healthcare Cost Impact of Continued Anticoagulation Therapy with Rivaroxaban Versus Aspirin for Prevention of Recurrent Symptomatic Venous Thromboembolism in the Einstein Choice Trial Population

Bruce L. Davidson, MD MPH, Philip S. Wells, MD FRCPC, MSc, Martin H. Prins, MD PhD, Jan Beyer-Westendorf, MD, Anthonie WA. Lensing, MD PhD, Lloyd Haskell, MD, Bennett Levitan, MD PhD, François Laliberté, Veronica Ashton, MPH, Yongling Xiao, PhD, Dominique Lejeune, Concetta Crivera, Patrick Lefebvre, MA, Qi Zhao, MPH, Zhong Yuan, MD PhD, Jeff Schein, Paolo Prandoni, MD PhD

Blood (2017) 130 (Supplement 1): 218.

https://doi.org/10.1182/blood.V130.Suppl_1.218.218

Published: 2017

Journal Articles

VTE Recurrence and Safety of Anticoagulants Among Patients with Cancer Treated for Venous Thromboembolism

Alok A. Khorana, MD, Keith McCrae, MD, Dejan Milentijevic, Nora McCormick, François Laliberté, Concetta Crivera, Patrick Lefebvre, MA, Dominique Lejeune, Heather Rozjabek, Jeff Schein, Michael B. Streiff

Blood (2017) 130 (Supplement 1): 4631.

https://doi.org/10.1182/blood.V130.Suppl_1.4631.4631

Published: 2017

Journal Articles

Healthcare Costs Associated with Venous Thromboembolism in Cancer Patients Treated with Anticoagulants

Michael B. Streiff, Keith McCrae, MD, Dejan Milentijevic, Nora McCormick, François Laliberté, Concetta Crivera, Patrick Lefebvre, MA, Dominique Lejeune, Heather Rozjabek, Jeff Schein, Alok A. Khorana, MD

Blood (2017) 130 (Supplement 1): 4640.

https://doi.org/10.1182/blood.V130.Suppl_1.4640.4640

Published: 2017

Journal Articles

Risk of Venous Thromboembolism Recurrence Among Rivaroxaban Treated Patients Who Continued Versus Discontinued Therapy: Analyses Among VTE Patients

Alok A. Khorana, MD, Jeffrey S Berger, MD, Philip S Wells, MD, Roger Seheult, MD, Veronica Ashton, MPH, François Laliberté, MA, Concetta Crivera, PharmD, MPH, Dominique Lejeune, MA, Jeff Schein, DrPH, MPH, Peter Wildgoose, PhD, Patrick Lefebvre, MA, Scott Kaatz, DO, MSc

Blood (2016) 128 (22): 144.

https://doi.org/10.1182/blood.V128.22.144.144

Published: 2016

Journal Articles

Safety of Anticoagulant Therapies for Treatment of Venous Thromboembolism in Patients with Cancer

Michael Streiff, MD, Dejan Milentijevic, Keith McCrae, Daniel Yannicelli, Jonathan Fortier, Winnie Nelson, François Laliberté, MA, Concetta Crivera, PharmD, MPH, Patrick Lefebvre, MA, Jeff Schein, DrPH, MPH, Alok A. Khorana, MD

Blood (2016) 128 (22): 1178.

https://doi.org/10.1182/blood.V128.22.1178.1178

Published: 2016

Journal Articles

Reduced Costs and Length-of-Stay Associated with Rivaroxaban As Compared to Parenteral Bridging and Warfarin in Pulmonary Embolism Patients Managed in Observation Status

Christine G Kohn, PharmD, Erin R Weeda, PharmD, W Frank Peacock, MD FACEP, Gregory J Fermann, MD, Christopher W. Baugh, MD MBA, Philip S Wells, MD FRCPC, MSc, Veronica Ashton, MPH, Concetta Crivera, PharmD, MPH, Peter Wildgoose, PhD, Jeff Schein, DrPH, MPH, Craig I Coleman, PharmD

Blood (2016) 128 (22): 2337.

https://doi.org/10.1182/blood.V128.22.2337.2337

Published: 2016

Journal Articles

Healthcare Resource Utilization and Costs Associated with Venous Thromboembolism Recurrence in Patients with Cancer

Alok A. Khorana, MD, Keith R. McCrae, MD, Dejan Milentijevic, Jonathan Fortier, François Laliberté, MA, Concetta Crivera, PharmD, MPH, Patrick Lefebvre, MA, Jeff Schein, DrPH, MPH

Blood (2016) 128 (22): 4734.

https://doi.org/10.1182/blood.V128.22.4734.4734

Published: 2016

Journal Articles

Validation of the Inhospital Mortality for Pulmonary Embolism Using Claims Data (IMPACT) Prediction Rule within an All-Payer Inpatient Administrative Claims Database

Craig I Coleman, PharmD, Christine G Kohn, PharmD, Concetta Crivera, Jeff Schein, W Frank Peacock, MD FACEP

Blood (2015) 126 (23): 747.

https://doi.org/10.1182/blood.V126.23.747.747

Published: 2015

Journal Articles

Does the Timing of Vital Sign Measurements Affect Simplified Pulmonary Embolism Severity Index (sPESI) Risk Determination?

Christine G Kohn, PharmD, Heather Rozjabek, MPH, Gregory J Fermann, MD, W Frank Peacock, MD FACEP, Concetta Crivera, Jeff Schein, Craig I Coleman, PharmD

Blood (2015) 126 (23): 2058.

https://doi.org/10.1182/blood.V126.23.2058.2058

Published: 2015

Journal Articles

Current Practice Patterns and Patient Persistence on Anticoagulant Treatments for Cancer-Associated Thrombosis

Alok A. Khorana, MD, Keith McCrae, Dejan Milentijevic, Jonathan Fortier, Winnie Nelson, François Laliberté, Concetta Crivera, Patrick Lefebvre, Daniel Yannicelli, Jeff Schein

Blood (2015) 126 (23): 626.

https://doi.org/10.1182/blood.V126.23.626.626

Published: 2015

NARROW

Cost per Responder Analysis to Assess the Value of CAR-T Therapy for Relapsed or Refractory Multiple Myeloma

Total Car-T Cost of Care Beyond the Price of Car-T Cell Therapy in Patients with Multiple Myeloma

Considerations for Optimal Administration of Chimeric Antigen Receptor (CAR) T-Cell Therapy Programs: A Multi-Stakeholder Qualitative Analysis

Healthcare Cost Impact of Continued Anticoagulation Therapy with Rivaroxaban Versus Aspirin for Prevention of Recurrent Symptomatic Venous Thromboembolism in the Einstein Choice Trial Population

VTE Recurrence and Safety of Anticoagulants Among Patients with Cancer Treated for Venous Thromboembolism

Healthcare Costs Associated with Venous Thromboembolism in Cancer Patients Treated with Anticoagulants

Risk of Venous Thromboembolism Recurrence Among Rivaroxaban Treated Patients Who Continued Versus Discontinued Therapy: Analyses Among VTE Patients

Safety of Anticoagulant Therapies for Treatment of Venous Thromboembolism in Patients with Cancer

Reduced Costs and Length-of-Stay Associated with Rivaroxaban As Compared to Parenteral Bridging and Warfarin in Pulmonary Embolism Patients Managed in Observation Status

Healthcare Resource Utilization and Costs Associated with Venous Thromboembolism Recurrence in Patients with Cancer

Validation of the Inhospital Mortality for Pulmonary Embolism Using Claims Data (IMPACT) Prediction Rule within an All-Payer Inpatient Administrative Claims Database

Does the Timing of Vital Sign Measurements Affect Simplified Pulmonary Embolism Severity Index (sPESI) Risk Determination?

Current Practice Patterns and Patient Persistence on Anticoagulant Treatments for Cancer-Associated Thrombosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only